Medigene AG Announces Appointment of Dr. Kirsty Crame, MD, as Head of Clinical Research & Development
20 mars 2023 06h00 HE
|
Medigene AG
Martinsried/Munich, March 20, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early stage immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene to present first pre-clinical data for MDG1015 with poster presentation at AACR 2023 Annual Meeting
16 mars 2023 05h00 HE
|
Medigene AG
Martinsried/Munich, March 16, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early stage immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene AG to report full year 2022 financial results on March 29, 2023
15 mars 2023 11h47 HE
|
Medigene AG
Martinsried/Munich, March 15, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene Amends 2022 Financial Guidance
10 mars 2023 12h00 HE
|
Medigene AG
MARTINSRIED, Germany and MUNICH, Germany, March 10, 2023 (GLOBE NEWSWIRE) -- The Executive Management Board of Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage...
Medigene Presents First Results for Automated Manufacturing of T Cell Receptor Engineered T Cells
23 févr. 2023 08h00 HE
|
Medigene AG
MARTINSRIED, Germany and MUNICH, Germany, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Medigene AG (Medigene, FSE: MDG1, Prime Standard) is an early-stage immuno-oncology platform company focusing on the...
Medigene to Participate in the H.C. Wainwright Cell Therapy Virtual Conference
22 févr. 2023 10h00 HE
|
Medigene AG
MARTINSRIED, Germany and MUNICH, Germany, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the...
Medigene to Present at the 6th Annual CAR-TCR Summit Europe in London
15 févr. 2023 09h00 HE
|
Medigene AG
MARTINSRIED, Germany and MUNICH, Germany, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the...
Medigene AG Appoints Pamela Keck as Vice President of Investor Relations and Corporate Communications
01 févr. 2023 11h35 HE
|
Medigene AG
MARTINSRIED and MUNICH, Germany, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and...
Medigene Receives $3 Million Milestone Payment from 2seventy bio
18 janv. 2023 11h35 HE
|
Medigene AG
Milestone payment is related to the establishment of 2seventy bio’s strategic partnership with JW TherapeuticsPayment provides further validation of Medigene’s end-to-end platform MARTINSRIED,...
Medigene Announces Strategy and Corporate Update
15 nov. 2022 11h35 HE
|
Medigene AG
Company strategy focused on developing differentiated TCR-T therapies from its proprietary “end-to-end” platform to target solid tumors with high unmet needPipeline expansion and acceleration of lead...